2022.03.09
I-Mab today announced that two poster presentations featuring translational research data of enoblituzumab and preclinical data of TJ-C64B will be presented at AACR 2022.
2022.03.03
I-Mab today announced that the U.S. FDA has granted Orphan Drug Designation for TJ-CD4B for the treatment of gastric cancer including cancer of gastroesophageal junction.
2022.01.28
I-Mab announced the signing of a partnership agreement with the Hangzhou Qiantang New Area in China to manufacture its innovative drugs locally and accelerate its transition to commercialization.
2022.01.18
I-Mab today announced that the first patient has been dosed in its China phase 2 trial of lemzoparlimab in combination with the PD-1 antibody toripalimab in patients with advanced solid tumors.
2022.01.14
The senior management team of the Company have executed the share purchase plan with the open market purchase of 70,000 of the Company’s ADS in an aggregate amount of over US$2.6 million as of 14 Jan, 2022.
2022.01.12
I-Mab today announced that the first patient had been dosed in its China phase 2 study of efineptakin alfa in combination with pembrolizumab in patients with advanced solid tumors.
2022.01.06
I-Mab today announced that the senior management team have informed the Company of their intention to use their personal funds to purchase the Company's American depositary shares on the open market for an aggregate amount of minimum US$3 million and up to US$20 million no later than February 28, 20...
2021.12.31
I-Mab today announced its participation in the following conferences in January 2022.
2021.12.27
I-Mab announced that the CDE of China’s NMPA has approved I-Mab’s IND submission for the initiation of a phase 2 trial in China for enoblituzumabin combination with pembrolizumab in patients with solid tumors, including non-small cell lung cancer, urothelial carcinoma, and other selected cancers.
2021.12.20
I-Mab today announced strategic leadership changes and a new governance initiative designed to facilitate its global pipeline development and accelerate its ongoing transformation towards an integrated global biopharma company.